INAMIRIZIV

INAMIRIZIV is a South African anti-retroviral medication used to treat HIV/AIDS. It is a fixed-dose combination of two active ingredients: lamivudine and zidovudine. The drug is available in tablet form and is typically taken orally once daily. INAMIRIZIV is part of a class of medications known as nucleoside reverse transcriptase inhibitors (NRTIs), which work by inhibiting the reverse transcriptase enzyme, thereby preventing the replication of HIV in the body.

The medication is indicated for the treatment of HIV-1 infection in adults and adolescents weighing at least 35 kilograms. It is often used as part of a combination antiretroviral therapy (cART) regimen to suppress viral replication and reduce the risk of HIV transmission. INAMIRIZIV is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include nausea, vomiting, diarrhea, and headache. Serious side effects are rare but can include lactic acidosis, a condition characterized by an excess of lactic acid in the blood, which can be life-threatening.

The drug should be used under the supervision of a healthcare provider, who will monitor the patient's response to treatment and adjust the regimen as necessary. INAMIRIZIV is not recommended for use in patients with known hypersensitivity to any of its components. It is also contraindicated in patients with severe hepatic impairment, as the drug is metabolized in the liver. Pregnant and breastfeeding women should use the medication with caution and under medical guidance, as its safety in these populations has not been fully established.